CHICAGO, Illinois — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine...
treatment News
CHICAGO, Ill. — MAIA Biotechnology Inc., (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer...
CHICAGO, Illinois – MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new interim data for its ongoing THIO-101 Phase 2 trial in non-small cell lung cancer (NSCLC) and outlined key clinical milestones for 2024. In the latest available data from THIO-101 (November 13, 2023), 60...
CHICAGO, Ill. — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell...
ROCKVILLE, Md. — The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies...
Hopes that a malaria vaccine could be widely available by 2012 have risen with the start last week (26 May) of phase III trials of the world’s most advanced candidate. Five infants in Bagamoyo, Tanzania, have received GlaxoSmithKline’s RTS,S vaccine and 16,000 children aged two and under will receive the...
Salt Lake City, Utah – Doctors diagnosed Christopher Gregg, Ph.D., member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah and neuroscientist and professor of neurobiology and human genetics at the at the same institution, with stage 4 metastatic breast...
DUBLIN – Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society (ERS), which include use of Acthar® Gel (repository corticotropin injection) therapy in the clinical management of certain patients with pulmonary sarcoidosis, published in European Respiratory Journal.[1] The treatment...
DUBLIN, Ireland — Mallinckrodt plc, a global specialty pharmaceutical company, recently announced the publication of findings from a cost analysis of TERLIVAZ® (terlipressin) for injection for adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.This analysis assessed the treatment-related cost per patient response with TERLIVAZ plus albumin from...
CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis — DUBLIN – Mallinckrodt Plc, a global biopharmaceutical company, today announced the publication of results from its pivotal Phase 3 CONFIRM...